Literature DB >> 25363834

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.

Raynier Devillier1, Sarah Bertoli, Thomas Prébet, Françoise Huguet, Anne Etienne, Aude Charbonnier, Jérôme Rey, Eric Delabesse, Evelyne D'Incan, Anne Huynh, Didier Blaise, Christian Récher, Norbert Vey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25363834     DOI： 10.1002/ajh.23884

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

2.  Improved outcome for AML patients over the years 2000-2014.

Authors:  Sarah Bertoli; Suzanne Tavitian; Anne Huynh; Cécile Borel; Sarah Guenounou; Isabelle Luquet; Eric Delabesse; Audrey Sarry; Guy Laurent; Michel Attal; Françoise Huguet; Emilie Bérard; Christian Récher
Journal:  Blood Cancer J       Date:  2017-11-29       Impact factor: 11.037

3.  Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Authors:  Sarah Bertoli; Arthur Sterin; Suzanne Tavitian; Lucie Oberic; Loïc Ysebaert; Reda Bouabdallah; François Vergez; Audrey Sarry; Emilie Bérard; Françoise Huguet; Guy Laurent; Thomas Prébet; Norbert Vey; Christian Récher
Journal:  Oncotarget       Date:  2016-12-27

4.  Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

Authors:  Tapan M Kadia; Patrick K Reville; Gautam Borthakur; Musa Yilmaz; Steven Kornblau; Yesid Alvarado; Courtney D Dinardo; Naval Daver; Nitin Jain; Naveen Pemmaraju; Nicholas Short; Sa A Wang; Rebecca S S Tidwell; Rabiul Islam; Marina Konopleva; Guillermo Garcia-Manero; Farhad Ravandi; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2021-08       Impact factor: 30.153

5.  [Clinical observation of standard IA regimen as induction chemotherapy in 242 patients with newly diagnosed acute myeloid leukemia].

Authors:  J Y Huang; W X Liu; Y Lian; H H Zhao; H X Wu; H Lu; L J Chen; G S He; J Y Li; S X Qian
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.